How do I: Evaluate the safety and legitimacy of unproven cellular therapies?-Reference-Cited by-同舟云学术

How do I: Evaluate the safety and legitimacy of unproven cellular therapies?

Published:2022-02-10 Issue:3 Volume:62 Page:518-532
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:Transfusion

Author:

Guleria Indira¹²^ORCID,Los Angeles Muñiz Maria³,Wilgo Matthew⁴,Bapat Asawari⁵^ORCID,Cui Wanxing⁶,Hsu Yen‐Michael Sheng⁷^ORCID,Jeyaraman Madhan⁸⁹^ORCID,Muthu Sathish⁹¹⁰^ORCID,Rodriguez Federico¹¹,Fesnak Andrew¹²^ORCID,Celluzzi Christina¹³,Sesok‐Pizzini Deborah¹²,Reich‐Slotky Ronit¹⁴^ORCID,Spitzer Thomas²¹⁵

Affiliation:

1. Renal Transplant Program, Division of Renal Medicine, Department of Medicine Brigham and Women's Hospital Boston Massachusetts USA

2. Harvard Medical School Boston Massachusetts USA

3. Transfusion Medicine and Cellular Therapy Division, Department of Pathology Weill Cornell Medicine New York New York USA

4. New England Cord Blood Bank, Inc. New England Cryogenic Center. Inc. Marlborough Massachusetts USA

5. Department of Quality and Regulatory Affairs Infohealth FZE and Questar Enterprises Dubai UAE

6. Cell Therapy Manufacturing Facility, Department of Pathology and Laboratory Medicine MedStar Georgetown University Hospital, Gerorgetown Washington District of Columbia USA

7. Division of Hematology and Oncology, Department of Medicine University of Pittsburgh School of Medicine and UPMC Hillman Cancer Center Pittsburgh Pennsylvania USA

8. Department of Orthopaedics, Faculty of Medicine Sri Lalithambigai Medical College and Hospital, Dr MGR Educational and Research Institute Chennai India

9. Department of Biotechnology School of Engineering and Technology, Sharda University Greater Noida India

10. Department of Orthopaedics Government Medical College and Hospital Dindigul India

11. Collections and Processing Facility, Bone Marrow Transplant Program UF Health Shands Cancer Hospital Gainsville Florida USA

12. Department of Pathology and Laboratory Medicine Perelman School of Medicine at the University of Pennsylvania Philadelphia Pennsylvania USA

13. Department of Biotherapies Association for the Advancement of Blood and Biotherapies Bethesda Maryland USA

14. John Theurer Cancer Center Hackensack University Medical Center Hackensack New Jersey USA

15. Division of Hematology‐Oncology, Department of Medicine Massachusetts General Hospital Boston Massachusetts USA

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/trf.16814

Reference20 articles.

1. Marketing of unproven stem cell–based interventions: A call to action

2. Part 1: Defining unproven cellular therapies

3. Recent Court Ruling in Japan Exemplifies Another Layer of Regulation for Regenerative Therapy

4. Commentary on “Possible induction of acute disseminated encephalomyelitis (ADEM)-like demyelinating illness by intrathecal mesenchymal stem cell injection”

5. Vision Loss after Intravitreal Injection of Autologous “Stem Cells” for AMD

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unapproved and unproven cancer treatments in patients admitted to palliative care units;2024-08-09

2. Barriers and Solutions Towards Integrating Orthobiologics into Clinical Orthopaedic Practice;Indian Journal of Orthopaedics;2024-07-11

3. Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa;Journal of Applied Genetics;2024-03-09

4. A comprehensive review on the role of mesenchymal stromal/stem cells in the management of rheumatoid arthritis;Expert Review of Clinical Immunology;2024-01

5. Uncovering the gray zone: mapping the global landscape of direct-to-consumer businesses offering interventions based on secretomes, extracellular vesicles, and exosomes;Stem Cell Research & Therapy;2023-05-04